Skip to main content
. 2013 Apr 15;27(8):900–915. doi: 10.1101/gad.203984.112

Figure 5.

Figure 5.

Role of ERK kinases in SAPD. (A) Immunoblots showing the levels of indicated proteins in IMR90 cells expressing H-RasV12 (R) or a vector control (V) and shERK2 or a control shRNA (shCTR) 14 d after infection (n ≥ 3). (B) Immunoblots for proteins and conditions as in A but for HMECs (n = 3). (C) Immunoblots showing the levels of the indicated proteins in wild-type or Erk2−/− MEFs expressing oncogenic ras or a vector control 14 d after infection (n = 3). (D) Immunoblots for the indicated proteins in IMR90 cells with a vector control (V) or H-RasV12 (R) and treated with the indicated chemicals. The treatments started immediately after infection, and the medium was changed every 2 d. Cells were harvested 10 d after infection (n = 2).